Emerald Health Therapeutics Signs Letter of Intent to Supply Cannabis to Québec Market
April 03 2019 - 6:00AM
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX:
EMHTF) has signed a letter of intent to supply cannabis to the
Société Québécoise du Cannabis (SQDC), Quebec's sole legal
distributor of recreational cannabis. Under the agreement, Emerald
will supply cannabis to the SQDC from its Québec-based
Saint-Eustache facility, Verdélite, as well as from its 50%-owned
joint venture, Pure Sunfarms, in Delta, BC. Emerald will fulfill
its first supply order in Q2 2019.
“Québec’s population of 8.4 million is a sizable
market and we are pleased to be able to offer locally-grown,
quality cannabis products to the adult-use consumers throughout the
province,” said Dr. Avtar Dhillon, President and Executive Chairman
of Emerald. “Verdélite is now near completion of the build-out of
its 88,000 square foot indoor cultivation facility and has been
scaling up production in licensed areas of the operation. We expect
to be in full production and to also have nationwide distribution
for the recreational market in the months ahead.”
Emerald is currently delivering cannabis in
Ontario, British Columbia, Yukon, and Newfoundland and Labrador,
and has a signed sales agreement with Alberta Gaming, Liquor and
Cannabis (AGLC) and is registered by the Saskatchewan Liquor
and Gaming Authority (SLGA) to supply cannabis.
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. is a Canadian
licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint
venture in BC is licensed to cultivate in 1.03 million square feet
of the first of it’s two 1.1 million square foot greenhouses. The
capacity of each greenhouse is estimated to exceed 75,000 kg of
cannabis annually. The initial facility has been scaling up
production over the last four quarters and will be fully planted in
April. Emerald’s Verdélite operation in Québec is completing the
build out of its 88,000 square foot indoor cultivation facility and
is scaling up production. Emerald secured over 500 acres of hemp
harvest in 2018 and has contracted for approximately 1000 acres in
2019 to 2022, with the objective of extracting low-cost cannabidiol
(CBD). Emerald has secured exclusive strategic partnerships for
large scale extraction and softgel encapsulation, as well as for
proprietary technology to enhance cannabinoid bioavailability. Its
team is highly experienced in life sciences, product development,
large-scale agri-business, and marketing, and is focused on
developing proprietary, value-added cannabis products for medical
and adult-use customers.
Emerald is part of the Emerald Health group,
which represents a broad array of companies focused on developing
pharmaceutical, botanical, and nutraceutical products developed to
provide wellness and medical benefits by interacting with the human
body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more information or
contact: Rob Hill, Chief Financial Officer (800) 757 3536 Ext. #
5
Emerald Investor Relations (800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include projected job creation figures at our operating facilities;
production and processing capacity of various facilities; expansion
of facilities; and anticipated production costs.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; as well as the risk factors described in the
Company’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Apr 2023 to Apr 2024